2016
Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013
Olmsted G, Farrelly J, Post G, Smith J. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013. Journal Of Feline Medicine And Surgery 2016, 19: 568-575. PMID: 26951557, PMCID: PMC11128809, DOI: 10.1177/1098612x16638118.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaSquamous cell carcinomaToceranib phosphateCell carcinomaTreatment modalitiesFeline oral squamous cell carcinomaMetabolic toxicityNon-steroidal anti-inflammatory drugsCurrent treatment optionsFavorable toxicity profileCommon oral tumorAnti-inflammatory drugsMajority of catsAdditional therapyGastrointestinal toxicityGI toxicityMedian doseSurgical excisionTreatment delayPoor prognosisTreatment optionsOral tumorsDose reductionRadiation therapyToxicity profile
2012
Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases
Linderman M, Brodsky E, de Lorimier L, Clifford C, Post G. Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases. Veterinary And Comparative Oncology 2012, 11: 208-218. PMID: 22612638, DOI: 10.1111/j.1476-5829.2012.00320.x.Peer-Reviewed Original ResearchConceptsMedian survivalRetrospective studySurvival timeNon-steroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyOverall median survivalPalpable abdominal massTime of diagnosisMedian survival timeExocrine pancreatic carcinomaHigh metastatic rateMetastatic diseaseAbdominal massClinical presentationMetastatic ratePoor prognosisPrognostic indicatorAggressive tumorsDrug therapyAbdominal effusionPancreatic cancerClinical signsPancreatic carcinomaPatientsWeight loss